£20m to develop ECM-targeted cancer and fibrosis drugs from human tissue data
This article covers Engitix, a biotech startup, which has closed a £20m series A funding round to advance programmes targeting the extracellular matrix in cancer and fibrosis. The funding will support preclinical development across its ECM-targeted pipeline and expand its human tissue ECM dataset that underpins the discovery platform.
Engitix, a biotech startup, has closed a £20 million series A funding round to advance programmes that target the extracellular matrix (ECM) in cancer and fibrosis. The capital is earmarked to push preclinical development across its ECM-targeted pipeline and to expand the company’s human tissue ECM dataset that underpins its discovery platform.
Why it matters
Therapeutic strategies that focus on the ECM aim to intervene in the tissue microenvironments where disease processes are sustained. Engitix’s approach — building high-resolution datasets from human tissue to find disease-associated ECM signatures — is an attempt to make early-stage drug discovery more closely grounded in human biology than some traditional model systems.
If successful, the work could affect areas of high unmet need, notably solid tumours and fibrotic diseases, where preclinical models have frequently failed to predict clinical outcomes. The deal is notable for funding a platform-driven biotech at the preclinical-development stage rather than a single drug candidate.
Inside the product
Engitix combines large-scale human tissue profiling with drug discovery aimed at molecules that act within altered ECM environments. The company says it has one of the largest proprietary ECM datasets focused on solid tumours and fibrosis, and uses pattern recognition in that data to identify disease-linked signatures and targetable biology.
The stated goal is to translate those signatures into therapeutics designed to act precisely within diseased tissue microenvironments. Proceeds from the round will be used to continue preclinical work across the company’s oncology and fibrosis programmes and to broaden the dataset and platform capabilities that feed discovery.
Why investors are betting on Engitix
The £20 million series A extension is led by Netherton Investments. The fund is investing on behalf of Mike Platt, the co-founder and Managing Director of BlueCrest Capital Management.
The backer frames the bet as support for a data-driven, platform approach that links human tissue profiling to drug design. In the announcement, Mike Platt, Investor Director at Netherton Investments, said:
Engitix has developed a compelling strategy at the intersection of data, biology, and drug development. I’m pleased to continue supporting Engitix as it advances its programs in fibrosis and solid tumors.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Founder perspective
In the announcement, Giuseppe Mazza, Co-founder & CEO at Engitix, said:
Closing this financing strengthens our ability to translate Engitix’s unique ECM understanding into a growing pipeline of targeted therapeutics. Our platform and dataset position us to accelerate preclinical development across oncology and fibrosis programs and build differentiated, ECM-targeted therapeutics with the potential to meaningfully improve patient outcomes.
Mazza framed the raise as a way to convert the company’s ECM dataset and platform into multiple preclinical programmes rather than advancing a single candidate.
The bigger picture
This funding round fits a wider pattern of investors placing larger bets on platform-oriented biotech companies that emphasise human-derived data to reduce translational risk. The deal also underscores continued private capital availability for preclinical-stage biotech in the UK and Europe, particularly for approaches that claim to address weaknesses in conventional models.
As investors seek more predictive discovery methods, interest from biotech investors in human-tissue and microenvironment-focused platforms is likely to persist. Engitix’s next milestones to watch will be validation of its ECM signatures in translational studies and progression of lead programmes toward IND-enabling work, which will indicate whether the dataset-driven approach yields better clinical predictability.
They've invested in Engitix
Get to know these biotech investors
Click here for a full list of 7,526+ startup investors in the UK